1-Boc-4-(4-Bromophenoxy)piperidine

Catalog No. :
ACRBML352
CAS No. :
308386-38-1
Molecular Formula :
C16H22BrNO3
Molecular Weight :
356.26

IUPAC Name:tert-butyl 4-(4-bromophenoxy)piperidine-1-carboxylate

1-Boc-4-(4-Bromophenoxy)piperidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$100.00Login to see priceIn stockIn stock
25g95%$481.00Login to see priceIn stockIn stock
100g95%$1488.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Boc-4-(4-Bromophenoxy)piperidine
IUPAC Nametert-butyl 4-(4-bromophenoxy)piperidine-1-carboxylate
MDL No.MFCD11053889
Molecular FormulaC16H22BrNO3
Molecular Weight356.26
SMILESCC(C)(C)OC(=O)N1CCC(CC1)OC1=CC=C(Br)C=C1
InChI KeyCOZKMQIFQZKKBR-UHFFFAOYSA-N
Synonym1-BOC-4-(4-bromophenoxy)piperidine | 308386-38-1 | 1-N-Boc-4-(4-Bromophenoxy)piperidine | tert-butyl 4-(4-bromophenoxy)piperidine-1-carboxylate | MFCD11053889 | SCHEMBL2366151 | DTXSID40674648 | COZKMQIFQZKKBR-UHFFFAOYSA-N | AKOS015836927 | AC-9191 | AS-37116 | SY065939 | CS-013
CAS No.308386-38-1
PubChem CID46739006

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACRBML352 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRBML352 route product structure diagram
    ACRBML352308386-38-1 In Stock
Inquiry

2. ACRBML352 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRBML352 route product structure diagram
    ACRBML352308386-38-1 In Stock
Inquiry

Comments (0)